Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020440 (hypercapnia)
 7,939 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Rosiglitazone is a peroxisome proliferator active receptor. gamma agonist, which increases insulin sensitivity in adipose tissue, muscle, and liver. Rosiglitazone is a member of the thiazolidinedione group, and because of its significantly positive effect on glycemic control, it is especially preferred in type 2 diabetic patients with a high cardiovascular disease risk. This drug, because of its decreasing effect on insulin resistance, is used alone or combined with type 2 diabetic drugs. A 73-year-old female patient was admitted to the emergency department with dyspnea, pink frothing phlegm, cyanosis, and tiredness. She was lethargic, uncooperative, and had no orientation. In arterial blood gases, hypoxemia and hypercapnia were found. She was taken to the general intensive care unit, and oxygen was applied via mask. The patient had a history of 10 years of diabetes mellitus, hypertension, and atherosclerotic cardiac disease, and she was using rosiglitazone for the past 6 weeks. Her chest x-ray was taken, and acute pulmonary edema was diagnosed. In her last echocardiography, which was performed 1 year before, no signs indicating cardiac failure and pleural effusion could be found. Therefore, it was concluded that pulmonary edema occurred as a complication of rosiglitazone use. After stabilizing the patient's vital signs, blood glucose levels, and lactate levels, medical treatment of diabetes mellitus was rearranged, and she was discharged on the seventh day after her admittance. In a patient with diabetes mellitus who has been admitted to the intensive care unit because of acute pulmonary edema, for differential diagnosis, use of rosiglitazone should be kept in mind during the determination of treatment. Therefore, the authors aim to discuss the effect of rosiglitazone on creating acute pulmonary edema with a case report presentation.
 ...
PMID:Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus. 1669 44

Non-invasive ventilation (NIV) refers to the delivery of mechanical ventilation to the lungs using techniques that do not require an endotracheal airway. Essentially, there are two modalities: continuous positive airway pressure (CPAP) and pressure support ventilation (NIPSV). In acute pulmonary edema (APE) both modalities have shown a faster improvement in gas exchange and physiologic parameters with respect to conventional oxygen therapy. CPAP is a simple technique that may reduce preload and afterload, increasing cardiac output in some patients. It has been successfully used in APE in the last 30 years, demonstrating a reduction in the intubation rate and mortality. The most common level of pressure is 10 cmH(2)O. NIPSV is a more complex mode that requires a ventilator and experience. It is usually applied with an expiratory pressure (EPAP or PEEP), resulting in a bilevel pressure modality (BIPAP). This technique has been introduced most recently in APE and has also shown a reduction in the intubation rate and a tendency to reduce mortality. The inspiratory help may be particularly useful in those patients with fatigue and hypercapnia. However, this hypothetical advantage over CPAP has not been demonstrated in comparative trials. The ventilator is usually set at 5 cmH(2)O of EPAP and inspiratory pressure between 12 and 25 cmH(2)O, although initially, the level of pressure support is lower. It is essential to achieve a good adaptation and synchronicity between the patient and the ventilator, reducing leakage to a minimum. The use of facial masks, high FiO(2), and sedation with opiates are complementary maneuvers that may be recommended in this context in the majority of patients.
 ...
PMID:Non-invasive ventilation. 1749 79